» Articles » PMID: 16825092

Predictive Factors for Chronic Renal Failure One Year After Orthotopic Liver Transplantation

Overview
Journal Ren Fail
Publisher Informa Healthcare
Date 2006 Jul 11
PMID 16825092
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic renal failure (CRF) is increasingly prevalent in solid-organ-transplant patients. This is in part related to the long-term use of calcineurin inhibitor (CNI) agents. However, in orthotopic liver-transplant (OLT) patients, the effects of superimposed hepatitis C virus (HCV)-related renal lesions could also be a factor. The aim of this cohort study (February 2000 to September, 2003) was to identify the predictive factors at one year post-transplantation for CRF in OLT patients associated with induction therapies. CRF was defined as having a creatinine clearance (CC) lower than 60 mL/min. Of the 97 transplants performed during that period, 72 were still functioning after one year. Of these, 33 patients (45.8%) had CRF. In univariate analysis, the predicting factors for CRF were recipient sex (female), initial liver disease (HCV-related cirrhosis), pre-transplant CC (<80 mL/mn), and post-transplant serum creatinine >130 micromol/L at day 3 and months (M) 1, 3, and 6. In multivariate analysis, the independent predictive factors for CRF included female sex [OR: 11.5 (2.3-58.3); p = 0.003], HCV infection [OR: 5.01 (1.1-22.7); p = 0.03], pre-OLT CC <80 mL/mn [OR: 5.4 (1.2-23.7); p = 0.025], and serum creatinine at M6 greater than 130 micromol/L [OR: 19.6 (3.7-102.5); p = 0.0004]. Among all of the predictive factors for post-OLT CRF, only one is modifiable: post-transplant serum creatinine, which could be, to some extent, related to the long-term use of CNIs.

Citing Articles

Prognostic Factors of Renal Outcomes after Heart Transplantation: A Nationwide Retrospective Study.

Jeon J, Park H, Kim Y, Kang D, Lee J, Huh W J Clin Med. 2021; 10(21).

PMID: 34768634 PMC: 8584983. DOI: 10.3390/jcm10215110.


Sequential Cohort Analysis After Liver Transplantation Shows de Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction.

Lim T, McPhail M, Shah A, Mahgoub S, Nayagam J, Cramp M Transplant Direct. 2020; 6(2):e528.

PMID: 32095514 PMC: 7004634. DOI: 10.1097/TXD.0000000000000970.


Discovery and Validation of a Biomarker Model (PRESERVE) Predictive of Renal Outcomes After Liver Transplantation.

Levitsky J, Asrani S, Klintmalm G, Schiano T, Moss A, Chavin K Hepatology. 2019; 71(5):1775-1786.

PMID: 31509263 PMC: 7883482. DOI: 10.1002/hep.30939.


Cardiovascular Disease Outcomes Related to Early Stage Renal Impairment After Liver Transplantation.

VanWagner L, Montag S, Zhao L, Allen N, Lloyd-Jones D, Das A Transplantation. 2018; 102(7):1096-1107.

PMID: 29557907 PMC: 6023752. DOI: 10.1097/TP.0000000000002175.


Involvement of indirectly allostimulated CD4+CD43highCD45RO+ T cell proliferation in the development of chronic allograft nephropathy.

Wee Y, Jung J, Kim Y, Choi M, Kim Y, Choi D Exp Biol Med (Maywood). 2015; 241(11):1217-28.

PMID: 26350952 PMC: 4950307. DOI: 10.1177/1535370215601522.